Coronary Flow Velocity Reserve Declines After Anthracycline Therapy in Breast Cancer Patients

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS CJC Open Pub Date : 2024-05-01 DOI:10.1016/j.cjco.2024.01.009

Christopher Yu MBBS , Prajith Jeyaprakash MBBS , Koya Ozawa MD, PhD , Tomoko Negishi MD , Dhanusha Sabanathan MBBS, PhD , John Park MBBS, PhD , Jennifer Man MBBS, PhD , Anuradha Vasista MBBS, PhD , Faraz Pathan MBBS, PhD , Kazuaki Negishi MD, PhD, MSc

{"title":"Coronary Flow Velocity Reserve Declines After Anthracycline Therapy in Breast Cancer Patients","authors":"Christopher Yu MBBS , Prajith Jeyaprakash MBBS , Koya Ozawa MD, PhD , Tomoko Negishi MD , Dhanusha Sabanathan MBBS, PhD , John Park MBBS, PhD , Jennifer Man MBBS, PhD , Anuradha Vasista MBBS, PhD , Faraz Pathan MBBS, PhD , Kazuaki Negishi MD, PhD, MSc","doi":"10.1016/j.cjco.2024.01.009","DOIUrl":null,"url":null,"abstract":"<div><p>Anthracycline therapy (ANT) is associated with cancer therapy-related cardiac dysfunction. Coronary flow velocity reserve (CFVR) has shown prognostic utility in non-cancer cohorts, but no data have been obtained in a cardio-oncology setting. We investigated the acute effect of ANT on CFVR in breast cancer patients. A total of 12 female breast cancer patients undergoing ANT had pre- and post-ANT CFVR assessment. A significant decline in CFVR occurred (baseline: 2.66 ± 0.41 vs post-ANT: 2.47 ± 0.37, <em>P</em> = 0.016). This prospective study is the first to identify ANT-related coronary physiology changes in humans. Further studies are required to determine their clinical significance.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 5","pages":"Pages 768-772"},"PeriodicalIF":2.5000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24000453/pdfft?md5=93a4b3a3917e4830178721a89609f0af&pid=1-s2.0-S2589790X24000453-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X24000453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Anthracycline therapy (ANT) is associated with cancer therapy-related cardiac dysfunction. Coronary flow velocity reserve (CFVR) has shown prognostic utility in non-cancer cohorts, but no data have been obtained in a cardio-oncology setting. We investigated the acute effect of ANT on CFVR in breast cancer patients. A total of 12 female breast cancer patients undergoing ANT had pre- and post-ANT CFVR assessment. A significant decline in CFVR occurred (baseline: 2.66 ± 0.41 vs post-ANT: 2.47 ± 0.37, P = 0.016). This prospective study is the first to identify ANT-related coronary physiology changes in humans. Further studies are required to determine their clinical significance.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

乳腺癌患者接受蒽环类药物治疗后冠状动脉流速储备下降

蒽环类疗法（ANT）与癌症治疗相关的心脏功能障碍有关。冠状动脉血流速度储备（CFVR）在非癌症人群中显示出了预后效用，但在心脏病学环境中尚未获得相关数据。我们研究了 ANT 对乳腺癌患者冠状动脉血流速度储备的急性影响。共有 12 名女性乳腺癌患者接受了 ANT 前和 ANT 后的 CFVR 评估。CFVR出现了明显下降（基线：2.66 ± 0.41 vs ANT后：2.47 ± 0.37，P = 0.016）。这项前瞻性研究首次发现了 ANT 相关的人体冠状动脉生理变化。要确定其临床意义，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊